Delstrigo

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Delstrigo is a once-daily, fixed-dose, combination tablet of doravirine, lamivudine and tenofovir for the treatment of HIV-1 in adult patients with no prior antiretroviral treatment experience.

Delstrigo Overview

Reviewed: September 17, 2018
Updated: 

Delstrigo is a prescription medicine that is used without other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults who have not taken HIV-1 medicines before. It is a single product containing 3 medications: doravirine, lamivudine, and tenofovir disoproxil fumarate.

Delstrigo belongs to a group of drugs called antiretrovirals, more specifically non-nucleoside reverse transcriptase inhibitors (NNRTI) as well as nucleoside analogue reverse transcriptase inhibitors (NRTIs). These help to block essential enzymes needed by HIV to make copies of itself.

This medication comes in tablet form and is taken once a day, with or without food.

Common side effects of Delstrigo include nausea, and abnormal dreams. Delstrigo can also cause dizziness. Do not drive or operate heavy machinery until you know how Delstrigo affects you.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Delstrigo Drug Class

Back to Top

Delstrigo FDA Warning

Back to Top

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B

Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DELSTRIGO. If appropriate, initiation of anti-hepatitis B therapy may be warranted.